Trading Report: Today, Cytosorbents Corp (CTSO) Research Coverage Started at Brean Capital

Today, Cytosorbents Corp (CTSO) Research Coverage Started at Brean Capital

Brean Capital began coverage on shares of Cytosorbents Corp (OTCMKTS:CTSO) in a research report sent to investors on Tuesday. The firm issued a buy rating and a $24.00 target price on the stock.

Separately, Maxim Group reissued a buy rating on shares of Cytosorbents Corp in a research report on Wednesday, June 15th. Five equities research analysts have rated the stock with a buy rating, Cytosorbents Corp currently has a consensus rating of Buy and an average price target of $14.06.

Shares of Cytosorbents Corp (OTCMKTS:CTSO) opened at 5.63 on Tuesday. Cytosorbents Corp has a 52-week low of $3.11 and a 52-week high of $8.10. The firm has a 50-day moving average price of $5.70 and a 200-day moving average price of $4.79. The firm’s market capitalization is $143.21 million.

Cytosorbents Corp (OTCMKTS:CTSO) last posted its quarterly earnings results on Tuesday, August 9th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by $0.03. The company had revenue of $1.90 million for the quarter, compared to analysts’ expectations of $2.18 million. On average, equities research analysts anticipate that Cytosorbents Corp will post ($0.39) EPS for the current year.

Several hedge funds have recently bought and sold shares of the company. Advisor Group Inc. purchased a new stake in Cytosorbents Corp during the second quarter valued at $1,372,000. Raymond James & Associates raised its stake in Cytosorbents Corp by 318.6% in the second quarter. Raymond James & Associates now owns 324,603 shares of the company’s stock valued at $1,477,000 after buying an additional 247,052 shares during the last quarter. BlackRock Fund Advisors raised its stake in Cytosorbents Corp by 39.3% in the second quarter. BlackRock Fund Advisors now owns 53,915 shares of the company’s stock valued at $245,000 after buying an additional 15,203 shares during the last quarter. Vanguard Group Inc. raised its stake in Cytosorbents Corp by 1.0% in the second quarter. Vanguard Group Inc. now owns 537,707 shares of the company’s stock valued at $2,447,000 after buying an additional 5,446 shares during the last quarter. Finally, Douglass Winthrop Advisors LLC purchased a new stake in Cytosorbents Corp during the second quarter valued at $321,000.

Related posts

Leave a Comment